BioToxTech Co

BioToxTech Co Interest Coverage

The Interest Coverage Ratio of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is -8.49. In the previous year, Interest Coverage Ratio was -2.62 — a change of 223.77% (lower).

Interest Coverage

-8.49

YoY

223.77%

Last updated:

Interest Coverage Ratio of BioToxTech Co is 2024 -8.49 . Interest Coverage Ratio of BioToxTech Co was 2023 -2.62 . It decreases by 223.77% lower compared to the previous year.

The BioToxTech Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
3.92 KRW
Jan 1, 2018
0.01 KRW
Jan 1, 2019
-0.87 KRW
Jan 1, 2020
0.20 KRW
Jan 1, 2021
2.16 KRW
Jan 1, 2022
0.65 KRW
Jan 1, 2023
-2.62 KRW
Jan 1, 2024
-8.49 KRW
The BioToxTech Co Interest Coverage history
YEARInterest CoverageYoY
-8.49+223.77%
-2.62-503.93%
0.65-69.88%
2.16+989.01%
0.20-122.87%
-0.87-6,424.32%
0.01-99.65%
3.92-3.02%
4.04-131.78%
-12.71+90.59%
-6.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Interest Coverage Ratio of BioToxTech Co is -8.49 in 2024.

Interest Coverage Ratio of BioToxTech Co changed from -2.62 to -8.49, representing a 223.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioToxTech Co

All Key Metrics — BioToxTech Co